Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene have been associated with variations in nitric oxide (NO) formation and response to drugs in white subjects. We examined whether genetic polymorphisms (T-786C, b/a intron 4 and Glu298Asp) and haplotypes of the eNOS gene affect NO formation in 179 healthy black subjects. To assess NO formation, we measured the concentrations of nitrite in the plasma, red blood cells and whole blood. Although we found no effects of individual eNOS polymorphisms on NO formation, we found that the 'C-4b-Glu' haplotype is significantly more common in subjects with low circulating plasma and whole blood nitrite concentrations compared with subjects with high circulating nitrite concentrations (both Po0.0007). These findings reproduce previous findings in white subjects and are consistent with the idea that defining genetic markers is more important than ethnic classification, at least in terms of NO formation.
Introduction
Nitric oxide (NO) has an important role in cardiovascular homeostasis. 1 In the endothelial cells, NO is produced mainly by endothelial nitric oxide synthase (eNOS) and is quickly oxidized to nitrite (NO 2 À ), which is a useful index of endogenous NO formation because it reflects eNOS activity. 2, 3 Three clinically relevant polymorphisms in the eNOS gene have been widely studied because they may affect NO production: the T À786 C (rs 2070744), which is a single-nucleotide polymorphism in the promoter region, the Glu298Asp in exon 7 (rs1799983) and a 27-bp variable number of tandem repeats (VNTR) in intron 4. Pharmacogenetic studies have shown that polymorphisms in the eNOS gene may modify the effects produced by some drugs, including the increases in endogenous NO formation and other pleiotropic effects associated with statin therapy. [4] [5] [6] Recent studies have reported that some treatment options produce better effects in black subjects with hypertension and heart failure. 7 Although the use of race or ethnicity in medicine is very tricky, 7 recent trials have shown that the efficacy of cardiovascular drugs affecting NO formation differs in blacks compared with whites (see review in McNamara 8 ). However, these interethnic differences in drug responses may simply reflect interethnic differences in allele frequencies, and consequently haplotype distributions. 9 This is clearly the case of eNOS gene, and significant interethnic differences in the distribution of eNOS genotypes and haplotypes have been consistently described in different populations. [10] [11] [12] These differences may have significant effect on the responses to drugs that modify NO formation. 13 However, although few studies have examined the effects of eNOS polymorphisms on the endogenous NO formation in white subjects, 14, 15 there is no information regarding this issue in black subjects.
The objective of this study was to examine whether genetic polymorphisms and haplotypes of the eNOS gene, which were previously associated with variable concentrations of NO products 14, 15 in healthy white volunteers, could affect NO formation in healthy black subjects. The main hypothesis being tested in this study is that genetic variations in the eNOS gene would modify the concentrations of NO products in black subjects in parallel to those modifications that have been reported in white subjects. In general, we hypothesized that eNOS genetic markers would be the major determinants of NO formation, independently of ethnicity. To test our hypothesis, we measured the concentrations of nitrite in three blood components: plasma, red blood cells and whole blood. This is very important because red blood cell erythrocytes contain the majority of intravascular nitrite in whole blood. 16 Therefore, it is possible that whole blood nitrite concentrations may reflect NO formation better than plasma nitrite concentrations. 16 
Materials and methods

Subjects
This study was approved by the institutional review board at the Hospital São Rafael-Salvador-BA, and each subject provided written informed consent. This work was carried out in accordance with the ethics standards of the Helsinki Declaration. We studied 179 healthy volunteers (age range 18-63 years) who were nonsmokers, recruited from Salvador-BA (Brazil) and self-reported as blacks. Because the Brazilian population is heterogeneous, we have not studied subjects self-reported as intermediate. Arterial blood pressure and heart rate were measured three times after at least 15 min of rest. Venous blood samples were collected after the subjects gave informed consent.
Genomic DNA was extracted from the cellular component of 1 ml of whole blood by a salting-out method and stored at À20 1C until analyzed. 17 
Genotype determination
Three clinically relevant polymorphisms in the eNOS gene were studied: the T À786 C polymorphism in the 5 0 -flanking region of the eNOS gene, the VNTR, the 27-bp repeat polymorphism in intron 4, and the Glu298Asp polymorphism in exon 7. Genotypes for the T À786 C and Glu298Asp polymorphisms were determined by Taqman Allele Discrimination assay and real-time PCR on Chromo 4 Detector (Bio-Rad Laboratories, Hercules, CA, USA). TaqMan PCR amplification was performed in 12 ml volumes (3 ng dried DNA, 1 Â TaqMan master mix, 900 nM of each primer and 200 nM of each probe) in 96-well PCR plates, and fluorescence from PCR amplification was detected using a Chromo 4 Detector (Bio-Rad Laboratories) and analyzed with its software. The PCR assay was carried out following the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA) that included one step of 10 min at 95 1C (Ultra Pure AmpliTaq Gold DNA Polymerase Enzyme Activation) followed by 40 cycles of DNA denaturation at 92 1C for 15 s and annealing/extension at 60 1C for 1 min. 18 However, genotypes for the VNTR polymorphism in intron 4 were determined by PCR and fragment separation by electrophoresis in 8% polyacrylamide gels, as previously described.
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Measurement of nitrite concentrations in plasma, red blood cells and whole blood samples Venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson Sáo Paulo, Brazil) containing heparin and immediately centrifuged at 1000 g for 3 min. Plasma aliquots were then immediately removed and stored at À70 1C until analyzed in triplicate for their nitrite content using an ozone-based chemiluminescence assay, as described previously. 19 In brief, 200 ul of plasma samples were injected into a solution of acidified triiodide, purging with nitrogen in-line with a gas-phase chemiluminescence NO analyzer (Model 280, NO analyzer; Sievers Boulder, CO, USA). 20 Approximately 8 ml of triiodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 ml of water with 140 ml of acetic acid) was placed in the purge vessel into which plasma samples were injected. The triiodide solution reduced nitrites to NO gas, which was detected by the NO analyzer.
To measure whole blood nitrite or red blood cells nitrite concentrations in triplicate, venous blood samples (or red blood cells separated by centrifugation as described above) were collected into tubes and immediately mixed with a nitrite preservation solution in a 5:1 dilution as previously described. 5 In brief, this solution contains 0.8 M ferricyanide and 1% NP-40. The samples were deproteinated with methanol (1:1) and centrifuged at 14 000 g for 5 min. Then, 200 ml supernatant was injected into the solution of acidified triiodide and purged with nitrogen in-line with a gas-phase chemiluminescence NO analyzer, as described above.
Measurement of thiobarbituric acid-reactive species in plasma
Thiobarbituric acid-reactive species were determined in plasma samples as previously described. 21 In short, 0.2 ml of sample was added to the reaction mixture containing 0.5 ml of 1% phosphoric acid (pH 2.0), 0.25 ml aqueous solution of 0.6% thiobarbituric acid (final volume of 1.0 ml), followed by 60 min of heating at 95 1C. After cooling, samples and standards of malondialdehyde were read at 532 nm against the blank of the standard curve.
Haplotype inference
Haplotypes were inferred using the Bayesian statistical-based program PHASE version 2.1 (http://www.stat.washington. edu/stephens/software.html) 22 to estimate the haplotype frequencies in the population and the two haplotypes for each subject. These results were used to evaluate the relationship between eNOS haplotypes and nitrite concentrations in plasma, red blood cells and whole blood samples. The possible haplotypes, including genetic variants of three eNOS polymorphisms studied, were: H1(T-4b-Glu), H2(T-4b-Asp), H3(T-4a-Glu), H4(T-4a-Asp), H5(C-4b-Glu), H6(C-4b-Asp), H7(C-4a-Glu) and H8 (C-4a-Asp).
Statistical analysis
The distribution of genotypes for each polymorphism was assessed for deviation from the Hardy-Weinberg equilibrium using w 2 tests (StatView, Cary, NC, USA). To assess potential relationships between each polymorphism and nitrite concentrations (in plasma, red blood cells and whole blood), we used the Kruskal-Wallis test followed by the Dunn's multiple comparison test. We used w 2 tests to compare the distribution of genotypes, alleles and the estimated haplotype frequencies in subjects with the 30 lowest (L group) nitrite concentrations with those in subjects with the 30 highest (H group) nitrite concentrations measured in plasma samples. Thereafter, we repeated this procedure taking into consideration nitrite concentrations in red blood cells, and repeated it again taking into consideration nitrite concentrations in whole blood samples. To compare nitrite concentrations (in plasma, red blood cells and whole blood) in the L group with those in the H group, we used the Mann-Whitney test. Because we compared the frequencies of eight different haplotypes between the two groups (L and H), a corrected P-value of o0.0063 ( ¼ 0.05/8, which would allow eight simultaneous comparisons) was considered significant. Otherwise, a P-value of o0.05 was considered to be statistically significant. Normally distributed data were reported as the mean ± s.d., whereas non-normally distributed date were reported as the median and interquartile range.
Results
To assess endogenous NO formation, we studied nitrite concentrations in plasma, red blood cells and whole blood samples from 179 healthy black male subjects. We carried out an analysis that was similar to that previously reported by us in a study of healthy white subjects. 15 We compared the distribution of genotypes, alleles and the estimated haplotype frequencies in subjects with the 30 lowest (L group) nitrite concentrations with those in subjects with the 30 highest (H group) nitrite concentrations measured in plasma, red blood cells and whole blood samples. Table 1 summarizes the clinical and laboratorial characteristics of the L and H groups. We found no significant differences in age, body mass index, systolic and diastolic arterial blood pressure, heart rate and malondialdehyde concentrations in plasma (Table 1 ; all P40.05).
Interestingly, in addition to the two commonly described alleles (4b and 4a), which have five and four 27-bp repeats, respectively, we detected two additional variants for the VNTR polymorphism in intron 4. The variants 4c and 4y, which correspond to six and two 27-bp repeats, respectively, have been observed previously. 12 Because the number of subjects carrying these rare variants was very small (see Table 2 ), we decided to exclude these subjects from the analysis.
The distribution of genotypes for the three polymorphisms studied here showed no deviation from Hardy-Weinberg equilibrium (all P40.05). When the allele and genotype frequencies were compared between the L and H groups, no significant differences were found (Table 2 ; all P40.05). Similarly, we found no significant effects of genotypes on nitrite concentrations in plasma, red blood cells or whole blood (Table 3 ; all P40.05).
Differences between the two groups (L and H) in haplotype frequencies were assessed using w 2 tests. Because Table 1 Clinical and laboratorial characteristics of study groups 756.7 (659.9-1012.0) * Abbreviations: BMI, body mass index; DAP, diastolic arterial pressure; HR, heart rate; MDA, thiobarbituric acid-reactive species concentrations in plasma measured as malondialdehyde; NS, nonsignificant; RBC, red blood cell; SAP, systolic arterial pressure. *Po0.0001.
P-values for 'L' compared with 'H'.
Values are the mean ± s.d. for normally distributed data, or the median (interquartile range) for non-normally distributed data.
Endothelial NOS haplotypes and nitrite in blacks
IF Metzger et al
we compared the frequencies of eight different haplotypes between the two groups, a corrected P-value of o0.0063 ( ¼ 0.05/8, which would allow eight simultaneous comparisons) was considered significant. Interestingly, the analysis of plasma nitrite concentrations showed that although the frequencies of seven out of eight possible haplotypes were not significantly different in the L group compared with the H group (Table 4 ; P40.05), the haplotype including the 'C', '4b' and 'Glu' alleles for the polymorphisms in the promoter region, in intron 4, and in exon 7, respectively, was significantly more common in the L group (11.2%) than in the H group (0.0%; Table 4 ; P ¼ 0.0007). In parallel with this finding, the analysis of whole blood nitrite concentrations showed that the same C-4b-Glu haplotype was significantly more common in the L group (12.4%) than in the H group (0.0%; Table 4 ; P ¼ 0.0003). The analysis of nitrite concentrations in red blood cells, however, showed only a trend for similar results (Table 4 ; P ¼ 0.0398, which is not significant after correction for multiple comparisons).
Discussion
This is the first study to investigate the influence of eNOS gene variations and haplotypes on NO formation in black subjects. Although we found no effects of individual eNOS polymorphisms on NO formation, they may have significant effects when combined within a specific haplotype, thus significantly affecting in vivo NO bioavailability.
Our findings showed that the 'C-4b-Glu' haplotype is significantly more common in subjects with low circulating plasma and whole blood nitrite concentrations compared with subjects with high circulating nitrite concentrations, even when correction for multiple comparisons was carried out. These findings are consistent with a major contribution of eNOS haplotypes to variation in NO formation that is obscured when specific eNOS genotypes alone are considered. Interestingly, these findings confirm previous findings reported in white subjects. 14, 15 In addition, the analysis of nitrite concentrations measured in red blood cells have not Table 2 Genotypes and allele frequencies in the L and H groups These genotype groups were excluded from the analysis because they are very rare. Statistical analysis: genotypes were compared using w 2 test, and alleles were compared using Fisher's test.
reached statistical significance. However, this biomarker of NO formation tended to confirm our findings in plasma and whole blood samples. Together, these results suggest that the 'C-4b-Glu' haplotype may have a negative effect on NO formation in white and in black subjects, although major interethnic differences exist in the distribution of eNOS haplotypes.
11,12
Nitrite has been considered a major storage pool for NO in the circulation. [23] [24] [25] In fact, nitrite concentrations in red blood cells are much higher than those found in plasma. 26 Therefore, it is possible that whole blood nitrite concentration is the most reliable index of endogenous NO formation. 16, 27 However, low plasma nitrite levels indicate endothelial dysfunction, and these levels correlate with cardiovascular risk factors. 27, 28 Although the subjects included in this study were free from any clinical disease, it is possible that some of them may develop cardiovascular diseases with time. Therefore, it is possible that our findings associating nitrite concentrations in plasma, whole blood and red blood cells with eNOS haplotypes may explain the association of genetic variations in the eNOS gene and the development of cardiovascular diseases. 29, 30 Many recent studies have reported interethnic differences in vascular reactivity and in endogenous NO formation or responses to drugs. [31] [32] [33] [34] [35] [36] [37] [38] Previous findings 11, 12 and those reported in this study suggest that eNOS haplotypes have similar effects on NO formation, independently of ethnicity. Therefore, it is reasonable to expect that interethnic differences in vascular reactivity, NO formation and responses to drugs that affect NO formation are due to interethnic differences in eNOS haplotype distributions. 11, 12 Consistent with this suggestion, it has been shown that eNOS haplotypes are associated with variable susceptibility to hypertensive disorders, independently of ethnicity. 18, [39] [40] [41] [42] This study, however, has some limitations. First, the relatively small number of volunteers (N ¼ 179) may have limited the power of our study to detect an effect of individual genotypes on the plasma, red blood cells or whole blood nitrite concentrations. However, this study confirms previous findings reported in white subjects. 14, 15 Second, all the volunteers enrolled in this study were men. Further studies aimed at identifying the specific eNOS haplotypes affecting NO formation in women are needed. In conclusion, our findings suggest that the 'C-4b-Glu' haplotype is associated with lower NO formation in blacks. It is possible that eNOS gene variants combined within a specific haplotype modulate NO formation independently of race, although individual eNOS polymorphisms probably do not have major effects. These findings suggest that defining genetic markers is more important than ethnic or racial classification, at least in terms of NO formation.
